The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
In this video, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, briefly discusses an abstract focusing on the impact of new or worsening thrombocytopenia on clinical outcomes in patients with JAK inhibitor–naive myelofibrosis (MF) treated with ruxolitinib. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This abstract presented by my friend and colleague Vikas Gupta, which I participated in, was really looking at real-world evidence and outcomes from patients with myelofibrosis treated with ruxolitinib. As we have kind of suspected throughout, that patients with new or worsening cytopenias, it really ends up having big implications in terms of the ability to fully dose ruxolitinib and with that comes compromises in terms of the quality of the benefit for splenomegaly and symptoms...
This abstract presented by my friend and colleague Vikas Gupta, which I participated in, was really looking at real-world evidence and outcomes from patients with myelofibrosis treated with ruxolitinib. As we have kind of suspected throughout, that patients with new or worsening cytopenias, it really ends up having big implications in terms of the ability to fully dose ruxolitinib and with that comes compromises in terms of the quality of the benefit for splenomegaly and symptoms. This is now an era where we have additional JAK inhibitors that can be more active in improving cytopenias as well as combination approaches that may have an impact on alleviating cytopenias, you know, just pushes us further to say that we need probably a different approach in these individuals. Sometimes they’ll end up in this situation, but there’s really a delay in them starting on new therapy. We think moving on to either available agents or clinical trials is very important.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
